A genome‐wide association study of European advanced cancer patients treated with opioids identifies regulatory variants on chromosome 20 associated with pain intensity

This genome-wide association study on European advanced cancer patients treated with opioids identifies novel regulatory variants on chromosome 20 (near PCMTD2 and OPRL1 genes) associated with pain intensity. These findings enhance our understanding of the genetic basis of opioid response, suggesting new potential markers for opioid efficacy. The study is a significant advancement in pharmacogenomics, providing a robust dataset and new insights into the genetic factors influencing pain intensity, which could lead to personalized cancer pain management.

Authors

Institutions

Publication Details

Journal
European Journal of Pain
Published
2024-12-04
DOI
https://doi.org/10.1002/ejp.4764
Citations
2
Primary Topic
Pain Management and Opioid Use
Type
article
Field-Weighted Citation Impact
1.28

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

A genome‐wide association study of European advanced cancer patients treated with opioids identifies regulatory variants on chromosome 20 associated with pain intensity

Pål Klepstad, Augusto Caraceni, Frank Skorpen, Oscar Corli et al.
2 citations
European Journal of Pain
Pain Management and Opioid Use
1.28
article

A genome‐wide association study of European advanced cancer patients treated with opioids identifies regulatory variants on chromosome 20 associated with pain intensity

Pål Klepstad, Augusto Caraceni, Frank Skorpen, Oscar Corli, Francesca Colombo, Francesca Minnai, Marco Maltoni, Ernesto Zecca, Morena Shkodra, Alessandra Pigni, Sara Noci, Cinzia Brunelli, Maria Caterina Pallotti, Martina Esposito, Stein Kaasa
article en
2 citations

Abstract

This genome-wide association study on European advanced cancer patients treated with opioids identifies novel regulatory variants on chromosome 20 (near PCMTD2 and OPRL1 genes) associated with pain intensity. These findings enhance our understanding of the genetic basis of opioid response, suggesting new potential markers for opioid efficacy. The study is a significant advancement in pharmacogenomics, providing a robust dataset and new insights into the genetic factors influencing pain intensity, which could lead to personalized cancer pain management.

European Journal of PainVol. 29(1)
Oslo University Hospital (NO), University of Oslo (NO), University of Milan (IT), Mario Negri Institute for Pharmacological Research (IT), Norwegian University of Science and Technology (NO), Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IT), St Olav's University Hospital (NO), Istituti di Ricovero e Cura a Carattere Scientifico (IT), Institute of Biomedical Technologies (IT), National Research Council (IT), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), University of Bologna (IT)
Associazione Italiana per la Ricerca sul Cancro
No poverty
Openalex Percentile: Top 17%
Pain Management and Opioid Use
1.28
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.